Compare ON & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ON | RMD |
|---|---|---|
| Founded | 1992 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5B | 34.0B |
| IPO Year | 2000 | 1996 |
| Metric | ON | RMD |
|---|---|---|
| Price | $74.10 | $222.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 10 |
| Target Price | $65.29 | ★ $292.56 |
| AVG Volume (30 Days) | ★ 8.3M | 1.1M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.13% |
| EPS Growth | N/A | ★ 9.67 |
| EPS | 0.48 | ★ 10.43 |
| Revenue | ★ $5,878,300,000.00 | $2,957,013,000.00 |
| Revenue This Year | $7.93 | $10.60 |
| Revenue Next Year | $8.90 | $7.41 |
| P/E Ratio | $151.78 | ★ $21.28 |
| Revenue Growth | N/A | ★ 13.44 |
| 52 Week Low | $44.56 | $180.27 |
| 52 Week High | $134.92 | $284.87 |
| Indicator | ON | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.50 | 47.59 |
| Support Level | $70.92 | $217.10 |
| Resistance Level | $74.98 | $233.94 |
| Average True Range (ATR) | 2.81 | 4.86 |
| MACD | 0.64 | -1.04 |
| Stochastic Oscillator | 75.30 | 38.48 |
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and one of the largest suppliers of image sensors to the automotive market. Its chips sell into vehicle drivetrains, automotive safety systems, energy infrastructure, industrial automation, and data centers. Onsemi manufactures most of its products in-house, vertically integrated from design to production. Its sales are split between direct and distribution, and it holds a global manufacturing and customer footprint.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.